Sionna Therapeutics Inc (SION)
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis. Its pipeline includes several CFTR-targeted candidates, such as galicaftor (SION-2222) and navocaftor (SION-3067), both of which have completed Phase 2 trials, as well as SION-109 and SION-2851, which have each completed Phase 1 studies. The company is also advancing SION-451 in a Phase 1 trial and SION-719 in a Phase 2a proof-of-concept trial. Founded in 2019 and formerly known as Sling Therapeutics, Inc., Sionna Therapeutics is headquartered in Waltham, Massachusetts. Its common stock is listed on NASDAQ under the symbol SION.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SION
|
$29.47
|
-37.4% Downside
|
Overvalued
|
$51.60
|
9.7% Upside
|
Fair
|
Great
|
—
|
—
|
—
|
0.0%
|
August 17, 2026
|
-24.9x
|
7.4x
|
—
|
2.063 B
|
1.849 B
|
0.4%
|
37.1%
|
72.0
|
—
|
84.3%
|
